Andrea Eleazar, MHS

FDA grants orphan drug designation to onvansertib for relapsed or refractory CMML, boosting development of the PLK1 inhibitor after early signals of activity.

New analysis reveals major gaps in US TNBC trial access, leaving rural and minority communities with fewer treatment options and research opportunities.

Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.

FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.

In patients 45+ with papillary thyroid cancer, men with dual BRAF V600E and TERT promoter mutations face sharply higher mortality, reshaping risk stratification.

Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.

Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.

ASH updates myelofibrosis care with expanded molecular testing, earlier transplant consultation, tailored JAK inhibitor use, anemia strategies, and aspirin guidance to reduce clot risk.

FDA accepts updated tab-cel BLA for EBV+ PTLD after transplant, adding ALLELE data; PDUFA decision set for March 31, 2027.

Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.

FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.

Real-world German MINT data show mogamulizumab delivers durable responses, ~20-month PFS, manageable safety, and improved quality of life in MF and Sézary syndrome.

Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies, yet gaps persist, and research funding uncertainty threatens future gains.

RYZ101, a targeted alpha radiopharmaceutical, boosts progression-free survival in SSTR+ GEP-NETs after progression, offering a promising post-¹⁷⁷Lu option.

ER status and HER2DX score predict complete response to neoadjuvant THP in HER2-positive breast cancer, guiding smarter, less intensive chemo selection.

Pan-cancer study shows age-based germline testing misses most inherited cancer variants, supporting broader genetic screening to guide treatment and family risk.

FDA grants 2 breakthrough therapy designations to Temab-A, speeding development for hard-to-treat colorectal cancer and c-Met–expressing lung cancer.

Interim phase 2 results show carotuximab plus apalutamide sharply extends progression-free survival in metastatic castration-resistant prostate cancer, prompting earlier-use trial changes.

Adding subcutaneous epcoritamab to R-CHOP significantly improves PFS in newly diagnosed DLBCL, potentially reshaping frontline therapy with a tolerable safety profile.

A cisplatin patch achieves 95.5% complete responses in early oral lesions, helping patients avoid surgery with durable control and minimal systemic toxicity.

Ohio Medicaid patients with breast cancer often miss genomic tests; use stays under 40%, with stage, race, and long-term care status driving disparities.

FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus bendamustine-rituximab.

Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.

Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.

Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.

Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.

FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.

Proton therapy did not improve overall survival vs photon therapy in advanced hepatocellular carcinoma in the phase 3 NRG-GI003 trial.

Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.

US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.